1210 ECP Faze
BioCentury & Getty Images

Emerging Company Profile

Launching with $81M, Third Rock’s Faze is latest biotech seeking to unravel biomolecular condensates biology

Emerging Company Profile: dissecting normal and pathogenic biomolecular condensate biology to enable drug development

Third Rock’s Faze has launched with an $81 million series A to develop therapeutics targeting biomolecular condensates, starting with ALS and myotonic dystrophy type 1.

Dec 11, 2020 | 1:34 AM GMT

Research into biomolecular condensates is gaining momentum with Third Rock launching the third company in the

Read the full 829 word article

How to gain access

Continue reading with a
two-week free trial.